Fibrosis is a disease characterized by repetitive injury and inflammation.
Lambda provides a lung and intestine fibrosis organoid model, enabling drug development and efficacy assessment.
*Please login to see the price
Fibrosis
Lambda’s Intestinal Fibrosis Model addresses these challenges by leveraging high mimetic human intestinal organoids to create a model of inflammatory bowel diseases. This model facilitates the evaluation of drug penetration concentrations and efficacy. It proves particularly valuable in the development of anti-fibrotic drugs, providing a reliable platform for assessing their efficacy.
Cell Type
· iPSC
Organoid type
· Intestinal organoid
Lambda’s IPF organoid model provides a highly mimetic representation of the structural and functional characteristics of human lung tissue, serving as a crucial platform for studying the mechanisms of pulmonary fibrosis, testing drug efficacy, and researching personalized treatment approaches.
Cell Type
· ASC
Organoid type
· Lung organoid
Intestinal fibrosis refers to the abnormal formation of excessive fibrous tissue in the walls of the intestine.
Fibrosis is a process in which normal tissue is replaced by scar tissue, which is composed mainly of collagen.
Lambda’s Intestinal Fibrosis Model addresses these challenges by leveraging high mimetic human intestinal organoids to create a model of inflammatory bowel diseases.
This model facilitates the evaluation of drug penetration concentrations and efficacy.
It proves particularly valuable in the development of anti-fibrotic drugs, providing a reliable platform for assessing their efficacy.
Organoid culture
2 weeks
Fibrosis-Induction
3-10 days
Drug treatment
1-2 days
Analysis (HCS,
Immunostaining, qPCR)
1-2 weeks
After inducing fibrosis in intestinal organoids, various inflammation-relieving drugs were treated at different concentrations to observe cell shape, and inflammatory markers were confirmed through qRT-PCR.
Lambda Biologics GmbH
Deutscher Pl. 5c, 04103 Leipzig, Germany
